Tosatoxumab(TD-IN998016) is a research-grade recombinant antibody targetingAlpha-hemolysin. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.
Species reactivity
Staphylococcus aureus
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species
Human
Isotype
IgG1-lambda
Clonality
Monoclonal
Target
Alpha-hemolysin, hly, Alpha-HL, Alpha-toxin, hla
Endotoxin level
Please contact the lab for this information.
Purity
>95% purity as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P09616
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names
KBSA301, 1374419-41-6
Background
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent.
Caption
SEC-HPLC detection for Research Grade Tosatoxumab. | Detects Alpha-toxin/hly in indirect ELISAs. | SDS-PAGE for Research Grade Tosatoxumab.
Note
For research use only. Not suitable for clinical or therapeutic use.